Abiopharma

🔍 Fitzgerald Joseph Michael (Executive)

Company: BOSTON SCIENTIFIC CORP (BSX)

Report Date: 2026-07-31

Detailed Transactions and Holdings:

• Acquired 64,198 shares of Common Stock at $46.73 per share (Direct)
  Date: 2026-07-31 | Code: I | equity_swap_involved: 0 | shares_owned_after: 64,198.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-31 | Code: H | shares_owned_after: 213,907.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-31 | Code: H | nature_of_ownership: By Child | shares_owned_after: 5,234.00 | Footnotes: F3

Footnotes:

• F1: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
• F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
• F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.